Key result
Total artificial heart support yields similar positive outcomes in CHD and non-CHD patients.
Why the study?
Patients with CHD often face barriers to VAD placement and may benefit from TAH-t, but differences in TAH application and outcomes between patients with and without CHD required evaluation.
Does total artificial heart (TAH-t) implantation provide similar outcomes in patients with congenital heart disease compared to those without?
Observational (n=1,876)
Yes
Does total artificial heart (TAH-t) implantation provide similar outcomes in patients with congenital heart disease compared to those without?
Total artificial heart implantation provides similar survival and support outcomes in patients with congenital heart disease compared to those without, supporting its use as a viable mechanical circulatory support option in this population.
Answers are grounded in this paper and cite their sources.
Similar TAH-t outcomes in CHD may support consideration; leaves open prospective confirmation before practice change.
Background: While ventricular assist devices (VADs) remain the cornerstone of mechanical circulatory support (MCS), the total artificial heart (TAH-t) has gained popularity for certain patients in whom VAD support is not ideal. Congenital heart disease (CHD) patients often have barriers to VAD placement due to anatomic and physiological variation and thus can benefit from the TAH-t. The purpose of this study is to analyze the differences in TAH application and outcomes in patients with and without CHD. Methods: The SynCardia Department of Clinical Research provided data upon request for all TAH-t implantations worldwide from December 1985 to October 2019. These patients were divided into two groups by pre-implantation diagnosis of CHD and non-CHD. Results: A total of 1,876 patients were identified. Eighty (4%) of these patients also carried a diagnosis of CHD. There was a higher proportion of children in the CHD cohort (16.3% vs. 2.1%, P<0.001) and this translated into a lower average age amongst the two groups (34±13 vs. 49±13 years, P<0.001). There were also significantly more females in the CHD group (22.8% vs. 12.8%, P=0.010). CHD patients were more likely to be supported with a 50 cc TAH-t (11.3% vs. 4.5%, P=0.005) while all other support characteristics, including duration of support, were similar between the groups. All measured outcomes were similar between CHD and non-CHD patients including positive outcome (alive on device or transplanted), 1-month conditional survival, and rate of Freedom Driver use. Conclusions: TAH-t is an effective means to support patients with CHD. Patients with CHD had similar survival, support characteristics, and frequency of discharge compared to patients without CHD. As MCS continues to grow, its indications broadened, and its contraindications narrowed, more patient populations will see the benefit of the TAH’s continuously developing technology.
No takes yet. Share an insight, caveat, or question.
Thangappan et al. (2020) conducted an observational in Heart failure requiring total artificial heart (n=1,876). Congenital heart disease vs. Non-congenital heart disease was evaluated on Positive outcome (alive on device or transplanted) (p=0.574). Congenital heart disease patients supported by a total artificial heart had similar rates of positive outcomes compared to non-congenital heart disease patients.
Synapse has enriched 10 related papers. Consider them for comparative context: